GERMANTOWN, Md., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today announced that Xi Chen, Ph.D., has been appointed to its Board
of Directors, effective immediately. Dr. Chen was appointed by Tianjin to replace Zhang Zhuo as the director appointee of the
Series A Convertible Preferred Stock.
“It is our pleasure to welcome Dr. Chen to the Board of Directors,” said Rich Daly, Chairman and CEO. “Dr. Chen comes to us with
years of therapeutic development and administrative expertise, and the contributions and guidance that he has to offer will be
highly valuable to the future of the Company.”
Dr. Chen has served as the Assistant General Manager of Manufacture, Equipment, and Administration at Tianjin Kinnovata
Pharmaceutical since 2014. He also served as the Deputy Director of the Marketing Department at Tianjin Pharmaceutical Holdings
since 2012. Previously, Dr. Chen was the Executive Vice General Manager of Tianjin Lights Medical Device Co., and a Research
Associate, Lab Manager at the University of Ottawa, and Anesthesiologist at Tianjin Union Hospital.
Dr. Chen. holds a PhD in Enterprises Management, a Master’s Degree in Molecular Biology from University of Ottawa, and a
Clinical Bachelor’s Degree from Tianjin Medical University.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet
medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical
development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke. NSI-566
is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral
Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell
technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by
words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30,
2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
